Specialty drugs

Aurinia Pharmaceuticals Announces Delisting from the Toronto Stock Exchange

Retrieved on: 
Friday, July 16, 2021
Biotechnology, Pharmaceutical, Health, Other Health, Life sciences, Biotechnology, Health sciences, Specialty drugs, Economy of Toronto, Toronto Stock Exchange, Biopharmaceutical

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company), a commercial stage biopharmaceutical company advancing therapies for severe autoimmune diseases, announced today it will voluntarily delist the common shares of the Company from the Toronto Stock Exchange (TSX) effective as of the close of trading on July 30, 2021.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company), a commercial stage biopharmaceutical company advancing therapies for severe autoimmune diseases, announced today it will voluntarily delist the common shares of the Company from the Toronto Stock Exchange (TSX) effective as of the close of trading on July 30, 2021.
  • Trading on the Nasdaq accounted for approximately 94 percent of Aurinias daily trading volume over the past 12 months.
  • The value of investor shares or stock options is not related to or dependent on the TSX listing.
  • Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need.

Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy

Retrieved on: 
Thursday, July 15, 2021
Life sciences, Biotechnology, Health sciences, Pharmaceutical industry, Pharmacy, Specialty drugs, Biopharmaceutical

These preclinical data demonstrate RTX-240s mechanism of action, which weve also seen translated to the clinic thus far.

Key Points: 
  • These preclinical data demonstrate RTX-240s mechanism of action, which weve also seen translated to the clinic thus far.
  • The monotherapy arm of the trial in advanced solid tumors includes a Phase 2 expansion in specified tumor types.
  • Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics.
  • Rubius initial focus is to advance RCT product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities potent cell-cell interaction and tolerance induction.

Bio-Thera Solutions Announces the First Patient Dosed in Phase III Clinical Trial for BAT2206, a Proposed Biosimilar of Stelara® (Ustekinumab)

Retrieved on: 
Thursday, July 15, 2021
Oncology, Health, Clinical trials, Research, Pharmaceutical, Science, Drugs, Life sciences, Health care, Biotechnology, Biosimilar, Specialty drugs, Immunosuppressants, Monoclonal antibodies, Bevacizumab, Ustekinumab

Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceutical company, today announced that the first patient has been dosed in a Phase III clinical study for BAT2206, a proposed biosimilar of Stelara (ustekinumab).

Key Points: 
  • Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceutical company, today announced that the first patient has been dosed in a Phase III clinical study for BAT2206, a proposed biosimilar of Stelara (ustekinumab).
  • BAT2206 is Bio-Thera's fourth biosimilar to enter a global phase III clinical study, commented Dr. Shengfeng Li, Founder and CEO of Bio-Thera Solutions.
  • Bio-Thera Solutions is developing several additional proposed biosimilars, including a bevacizumab biosimilar and a tocilizumab biosimilar that have both successfully completed global Phase III clinical trials.
  • 2 QLETLI is a registered trademark of Bio-Thera Solutions, Ltd.
    3 is a registered trademark of Bio-Thera Solutions, Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210715005583/en/

FDA Grants First Full Approval for Treatment of Lymphoma in Dogs

Retrieved on: 
Thursday, July 15, 2021
Food and Drug Administration, United States Public Health Service, Life sciences, Specialty drugs, Health, Biotechnology, Health policy in the United States

Tanoveais the first conditionally approved new animal drug for dogs to achieve the FDA's full approval.

Key Points: 
  • Tanoveais the first conditionally approved new animal drug for dogs to achieve the FDA's full approval.
  • "The FDA is dedicated to making treatment options available for all patients including animals suffering from rare conditions.
  • "We're committed to continue using all our authorities to help make limited-demand treatment options available to our animal companions."
  • "Today's approval shows that drugs to treat rare animal diseases, like canine lymphoma, can go through the FDA's conditional approval pathway to reach full approval.

Emmaus Life Sciences Announces Submission of Endari® Marketing Authorization Application in Kuwait

Retrieved on: 
Thursday, July 15, 2021
Life sciences, Biotechnology, Specialty drugs, Biopharmaceutical, Pharmaceutical industry, Pharmacy

TORRANCE, Calif., July 15, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA),a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today the submission of its application for Marketing Authorization (MA) for Endari to the Kuwait Drug and Food Control (KDFC).

Key Points: 
  • TORRANCE, Calif., July 15, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA),a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today the submission of its application for Marketing Authorization (MA) for Endari to the Kuwait Drug and Food Control (KDFC).
  • This is the first step in the registration of Endari by the KDFC, which is responsible for the registration of pharmaceutical products in Kuwait.
  • "We are pleased to announce the submission of our marketing authorization application to the Kuwaiti authorities.
  • Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories.

AllianceRx Walgreens Prime Connects Specialty Pharmacy Patients with More Than $600 Million in Financial Assistance

Retrieved on: 
Wednesday, July 14, 2021
Walgreens, Pharmacy, Specialty drugs, Health care, Retailers, Health sciences

That is why AllianceRx Walgreens Prime one of the largest specialty and home delivery pharmacies in the U.S. has dedicated team members who provide information on financial assistance programs available to eligible patients.

Key Points: 
  • That is why AllianceRx Walgreens Prime one of the largest specialty and home delivery pharmacies in the U.S. has dedicated team members who provide information on financial assistance programs available to eligible patients.
  • Over the last two years, AllianceRx Walgreens Prime has connected eligible patients1 to more than $600 million2 in financial assistance.
  • "While therapies for patients with chronic conditions have evolved greatly, they have done so at a price," says Lisa Mymo, vice president, Pharmacy and Financial Services at AllianceRx Walgreens Prime.
  • The amount of assistance to which AllianceRx Walgreens Prime connected patients in 2020 increased by nearly 14% over 2019.

Global TCR-based Therapies Markets 2021-2030 by Target Indications, Target Antigens, Key Players, Key Geographies, Industry Trends - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 13, 2021
Health, Other Health, Life sciences, Biotechnology, Health sciences, Specialty drugs, Biopharmaceutical, Pharmaceutical industry, Pharmacy, Immunology

The "TCR-based Therapies Market by Target Indications, Target Antigens, Key Players and Key Geographies, Industry Trends and Global Forecasts, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "TCR-based Therapies Market by Target Indications, Target Antigens, Key Players and Key Geographies, Industry Trends and Global Forecasts, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
  • The "TCR-based Therapies Market 2021-2030" report features an extensive study of the current market landscape and future potential of TCR-based therapies.
  • The report highlights the efforts of both industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry.
  • The contemporary TCR-based therapies market is characterized by a healthy and growing pipeline of close to 150 candidate therapies.

Amber Specialty Pharmacy to Dispense ADUHELM™ (aducanumab) for the Treatment of Alzheimer’s

Retrieved on: 
Thursday, July 8, 2021
Seniors, Pharmaceutical, Health, Mental health, Supermarket, Specialty, Consumer, Retail, Specialty drugs, Health insurance in the United States, URAC, Health sciences, Health care, Health, Pharmacy, Accreditation Commission for Health Care, Specialty pharmacy, Diplomat Pharmacy, Pharmacist

ADUHELM is the first new treatment for Alzheimers disease to be approved in the U.S. in nearly 20 years.

Key Points: 
  • ADUHELM is the first new treatment for Alzheimers disease to be approved in the U.S. in nearly 20 years.
  • Amber Specialty Pharmacy is a pioneer and leader in the specialty pharmacy industry with over 23 years of experience providing specialized care for persons with chronic, complex medical conditions.
  • Amber Specialty Pharmacy has built an outstanding reputation by providing personalized support and quality clinical care to patients and families.
  • Amber Specialty Pharmacy is accredited by the Utilization Review Accreditation Commission (URAC) and the Accreditation Commission for Health Care (ACHC).

ReCode Therapeutics to Present at William Blair Biotech Focus Conference 2021

Retrieved on: 
Thursday, July 8, 2021
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Life sciences, Biotechnology, Articles, Specialty drugs, Ciliopathy, Infertility, Primary ciliary dyskinesia, Biopharmaceutical, Arcturus Therapeutics

ReCode Therapeutics (the Company), a biopharmaceutical company pioneering disease-modifying genetic medicines using its SORT-LNPTM platform, today announced that CEO and President, David Lockhart, Ph.D., will participate in a panel discussion on non-viral drug delivery at the upcoming William Blair Biotech Focus Conference 2021 at 2:00 pm Eastern Time on Thursday, July 15, 2021.

Key Points: 
  • ReCode Therapeutics (the Company), a biopharmaceutical company pioneering disease-modifying genetic medicines using its SORT-LNPTM platform, today announced that CEO and President, David Lockhart, Ph.D., will participate in a panel discussion on non-viral drug delivery at the upcoming William Blair Biotech Focus Conference 2021 at 2:00 pm Eastern Time on Thursday, July 15, 2021.
  • An archived replay of the presentation will be made available on the Companys website following the presentation.
  • ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful, proprietary SORT-LNPTM platform to target organs and tissues beyond the liver.
  • The Companys pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia.

DGAP-News: Dermapharm Holding SE acquires equity investment in CORAT Therapeutics GmbH

Retrieved on: 
Wednesday, July 7, 2021
Life sciences, Biotechnology, Health sciences, Specialty drugs, Biopharmaceutical, Pharmaceutical industry, Pharmacy

Grnwald, 7 July 2021 - Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, is expanding its group of companies via Dermapharm AG to include an investment in the area of immunotherapies against COVID-19.

Key Points: 
  • Grnwald, 7 July 2021 - Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, is expanding its group of companies via Dermapharm AG to include an investment in the area of immunotherapies against COVID-19.
  • To this end, Dermapharm today concluded an agreement to invest in and acquire new shares in CORAT Therapeutics GmbH, based in Braunschweig.
  • CORAT Therapeutics GmbH was founded in May 2020 and holds patents in antibodies used for the treatment of human infectious diseases.
  • CORAT Therapeutics GmbH is a clinical phase biopharmaceutical company founded as a spin off from the recombinant antibody development company Yumab GmbH.